Roche ROP.SW
Roche is a multinational pharmaceutical and diagnostics company that develops and commercializes innovative medicines and diagnostic tests, with an integrated business model spanning from research to product sales. Roche maintains a solid balance sheet (ND/EBITDA 0.98) and an exceptional competitive moat (ROE 38.11%, operating margin 36.2%), but growth is negative (revenue -1.2%, earnings -7.7%) and valuation is not attractive (P/E 23.1). AI and bispecific R&D deals strengthen the mid-term pipeline, though the market has partially priced this in.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Roche is a multinational pharmaceutical and diagnostics company that develops and commercializes innovative medicines and diagnostic tests, with an integrated business model spanning from research to product sales. Roche maintains a solid balance sheet (ND/EBITDA 0.98) and an exceptional competitive moat (ROE 38.11%, operating margin 36.2%), but growth is negative (revenue -1.2%, earnings -7.7%) and valuation is not attractive (P/E 23.1). AI and bispecific R&D deals strengthen the mid-term pipeline, though the market has partially priced this in.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.7 |
| Quality / Moat | 8.7 |
| Valuation | 5.5 |
| Growth | 3.4 |
| Dividend | 6.5 |
| Momentum | 6.8 |
| Risk & Context | 8.3 |
OVERALL SCORE: 6.8/10
Context and risks
Moderate regulatory risk in Switzerland and drug pricing pressure in key markets, though no material open litigation. The macro rate environment does not materially affect a pharma company with ND/EBITDA of 0.98.
News considered in the analysis
- Roche Holding (SWX:ROP) Signed New AI Drug Discovery Partnerships — Refuerza la estrategia de I+D en IA, pero es un paso incremental sin impacto financiero inmediato.
- Roche and Earendil forge $1.5bn bispecific discovery deal — Acuerdo de colaboración de 1.500 millones de dólares que amplía el pipeline en bispecíficos, con potencial material a medio plazo.
- Roche targets Novartis on IgAN market after Phase III win — Victoria en fase III para nefropatía por IgA, un mercado relevante; compite directamente con Novartis y refuerza el pipeline.
- Merck remigromig DME trial results raise safety concerns — Noticia sobre un competidor (Merck) que podría beneficiar indirectamente a Roche, pero sin datos concretos sobre su impacto.
- Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine — Competidor de Merck presenta datos comparables en DME, lo que podría presionar la cuota de mercado de Lucentis/Vabysmo, aunque aún es preliminar.
Verdict: Hold: top-tier quality and balance sheet, but no clear short-term catalysts and stagnant growth; wait for pipeline maturation or a better valuation.
Main risk: Stagnant growth (revenue -1.2%) and competitive pressure in key areas like DME (Vabysmo) and IgA nephropathy, which could erode market share and delay earnings recovery.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →